December 20, 2024 03:05 PM EST
Pharma
FDA+

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Nicole DeFeudis

Editor

Pfiz­er scored an ac­cel­er­at­ed ap­proval Fri­day to bring its BRAF in­hibitor to first-line col­orec­tal can­cer pa­tients.

Braftovi was ap­proved in com­bi­na­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

US with­draw­al from WHO could jeop­ar­dize in­for­ma­tion shar­ing

Sanofi says no sup­ply in­ter­rup­tions af­ter land­ing FDA warn­ing let­ter for US site

Re­newed mifepri­s­tone fight will be ear­ly test of Trump’s abor­tion stance in his sec­ond term

J&J's Spra­va­to wins ex­pand­ed la­bel for de­pres­sion as sin­gu­lar treat­ment

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times